HomeCompareBMY vs NOW

BMY vs NOW: Dividend Comparison 2026

BMY yields 4.17% · NOW yields 1.91%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BMY wins by $98.0K in total portfolio value
10 years
BMY
BMY
● Live price
4.17%
Share price
$59.73
Annual div
$2.49
5Y div CAGR
37%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$120.5K
Annual income
$39,823.66
Full BMY calculator →
NOW
NOW
● Live price
1.91%
Share price
$104.97
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.5K
Annual income
$215.52
Full NOW calculator →

Portfolio growth — BMY vs NOW

📍 BMY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBMYNOW
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BMY + NOW cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BMY pays
NOW pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BMY
Annual income on $10K today (after 15% tax)
$354.34/yr
After 10yr DRIP, annual income (after tax)
$33,850.11/yr
NOW
Annual income on $10K today (after 15% tax)
$161.95/yr
After 10yr DRIP, annual income (after tax)
$183.19/yr
At 15% tax rate, BMY beats the other by $33,666.92/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BMY + NOW for your $10,000?

BMY: 50%NOW: 50%
100% NOW50/50100% BMY
Portfolio after 10yr
$71.5K
Annual income
$20,019.59/yr
Blended yield
28.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NOW right now

BMY
Analyst Ratings
19
Buy
20
Hold
2
Sell
Consensus: Hold
Price Target
$62.73
+5.0% upside vs current
Range: $40.00 — $75.00
Altman Z
2.3
Piotroski
8/9
NOW
Analyst Ratings
58
Buy
8
Hold
1
Sell
Consensus: Buy
Price Target
$196.29
+87.0% upside vs current
Range: $115.00 — $263.00
Altman Z
6.1
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BMY buys
0
NOW buys
0
No recent congressional trades found for BMY or NOW in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBMYNOW
Forward yield4.17%1.91%
Annual dividend / share$2.49$2.00
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR37%0%
Portfolio after 10y$120.5K$22.5K
Annual income after 10y$39,823.66$215.52
Total dividends collected$91.0K$2.0K
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusHoldBuy
Analyst price target$62.73$196.29

Year-by-year: BMY vs NOW ($10,000, DRIP)

YearBMY PortfolioBMY Income/yrNOW PortfolioNOW Income/yrGap
1← crossover$11,271$571.12$10,891$190.53+$380.00BMY
2$12,884$824.20$11,847$193.92+$1.0KBMY
3$14,993$1,206.32$12,873$197.15+$2.1KBMY
4$17,839$1,797.27$13,975$200.22+$3.9KBMY
5$21,826$2,738.11$15,156$203.13+$6.7KBMY
6$27,643$4,289.31$16,423$205.89+$11.2KBMY
7$36,534$6,955.64$17,781$208.50+$18.8KBMY
8$50,861$11,770.13$19,236$210.97+$31.6KBMY
9$75,402$20,980.23$20,796$213.31+$54.6KBMY
10$120,504$39,823.66$22,468$215.52+$98.0KBMY

BMY vs NOW: Complete Analysis 2026

BMYHealthcare

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Full BMY Calculator →

NOWStock

ServiceNow, Inc. provides enterprise cloud computing solutions that defines, structures, consolidates, manages, and automates services for enterprises worldwide. It operates the Now platform for workflow automation, artificial intelligence, machine learning, robotic process automation, performance analytics, electronic service catalogs and portals, configuration management systems, data benchmarking, encryption, and collaboration and development tools. The company also provides information technology (IT) service management applications; IT service management product suite for enterprise's employees, customers, and partners; IT business management product suite; IT operations management product that connects a customer's physical and cloud-based IT infrastructure; IT Asset Management to automate IT asset lifecycles; and security operations that connects with internal and third party. In addition, it offers governance, risk, and compliance product to manage risk and resilience; human resources, legal, and workplace service delivery products; safe workplace applications; customer service management product; and field service management applications. Further, it provides App Engine product; IntegrationHub enables application to extend workflows; and professional, industry solutions, and customer support services. It serves government, financial services, healthcare, telecommunications, manufacturing, IT services, technology, oil and gas, education, and consumer products through direct sales team and resale partners. It has a strategic partnership with Celonis to help customers identify and prioritize processes that are suitable for automation. The company was formerly known as Service-now.com and changed its name to ServiceNow, Inc. in May 2012. The company was founded in 2004 and is headquartered in Santa Clara, California.

Full NOW Calculator →
📬

Get this BMY vs NOW comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BMY vs SCHDBMY vs JEPIBMY vs OBMY vs KOBMY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.